COCP— Cocrystal Pharma, Inc.

MaterialsPharmaceuticals$15M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Research and development	$5.05B-59.7%	$12.54B-17.4%	$15.17B+122309.6%	$12.4M
General and administrative	$3.96B-25.8%	$5.34B-10.8%	$5.99B+104164.6%	$5.7M
Total operating expenses	$9.02B-49.6%	$17.88B-3.7%	$18.56B+47696.7%	$38.8M
Loss from operations	-$9.02B+49.6%	-$17.88B+3.7%	-$18.56B-47696.7%	-$38.8M
Interest income, net	$134.0M-75.0%	$537.0M-16.1%	$640.0M	—
Foreign exchange gain (loss)	$54.0M+133.1%	-$163.0M-150.8%	-$65.0M-361011.1%	-$18K
Total other income, net	$188.0M-49.7%	$374.0M-35.0%	$575.0M+7187600.0%	-$8K
Net loss	-$8.83B+49.5%	-$17.50B+2.7%	-$17.98B-46206.4%	-$38.8M
Net loss per common share, basic	-$780.00+54.7%	-$1720.00+8.0%	-$1870.00+60.8%	-$4770.00
Net loss per common share, diluted	-$780.00+54.7%	-$1720.00+8.0%	-$1870.00+60.8%	-$4770.00
Weighted average number of common shares outstanding, basic	11.3M+11.0%	10.2M+5.4%	9.7M+18.5%	8.1M
Weighted average number of common shares outstanding, diluted	11.3M+11.0%	10.2M+5.4%	9.7M+18.5%	8.1M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.